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Neurophysiological Mechanisms Underlying Elevated Blood Pressure and Sympathetic 
Activity in Sleep Apnea  
 
Introduction 
Sleep apnea is a common respiratory disorder characterized by transient, repetitive 
cessations in breathing during sleep. Because each cessation can last for tens of seconds, the 
disorder is often accompanied by an intermittent decrease in blood oxygen levels (i.e. hypoxia). 
There are two clinically distinct phenotypes of sleep apnea: obstructive sleep apnea (OSA), 
which is characterized by the partial or complete obstruction of the upper airways, and central 
sleep apnea (CSA), which arises due to the generation of defective respiratory rhythm by the 
central nervous system. Both phenotypes are associated with an increased risk of developing 
cardiovascular disorders such as hypertension (Floras, 2013). Although both OSA and CSA can 
co-occur, OSA is the most prevalent phenotype of sleep apnea, and is therefore the focus of this 
review. Previous studies have demonstrated that both neuronal and metabolic mechanisms are 
involved in the development of sleep apnea-induced hypertension, and that the resulting 
elevation of blood pressure is a risk factor for the development of stroke and heart failure 
(Narkiewicz et al., 1997; Aurora et al., 2013). During sleep, recurring episodes of hypoxia, 
normoxia and hypercapnia (elevated blood CO2 levels) act through various mechanisms to alter 
sympathetic drive in sleep apnea patients. In the long term, such alterations to the body’s 
homeostasis can have severe cardiovascular consequences. The objective of this review is to 
illustrate the neurophysiological mechanisms by which sleep apnea promotes the development 
and progression of elevated blood pressure, as well as to emphasize the increased cardiovascular 
risk present in patients with the disorder.  
 
 
  
Sleep apnea augments sensory activity of peripheral chemoreceptors in response to hypoxia 
Carotid and aortic bodies are peripheral sensory chemoreceptors that detect changes in 
blood oxygen levels. During hypoxia, these chemoreceptors increase sensory discharge to the 
medulla oblongata, where specialized neurons process the afferent traffic and respond by 
increasing sympathetic and ventilatory activity (Teppema & Dahan, 2010). The resulting 
increase in sympathetic activity ultimately leads to an elevation in blood pressure.  
Little controversy exists that intermittent hypoxia (IH), the recurring exposure to 
alternating periods of hypoxia and normoxia, is the major pathophysiological concomitant of 
sleep apnea responsible for blood pressure dysregulation (Aurora et al., 2013). Consequently, to 
elucidate the mechanisms involved in the pathogenesis and progression of sleep apnea, 
researchers often induce chronic IH in animal models to mimic the disorder (Pamidi et al., 2012). 
A suggested mechanism by which sleep apnea leads to elevated blood pressure is by augmenting 
the sensory activity of peripheral chemoreceptors in response to hypoxia (Fig. 1; Prabhakar, 
2000). In support of this suggestion, a study by Rey et al. (2004) revealed that inducing chronic 
IH in cats resulted in an enhanced sensitivity of carotid bodies to hypoxia. This enhanced 
hypoxic sensitivity is thought to be attributable, at least in part, to an IH-induced increase in 
oxidative stress (Prabhakar & Kumar, 2010). 
Oxidative stress refers to a state in which the production of reactive oxygen species 
(ROS) exceeds the body’s antioxidant defences. Previous research has shown that ROS, which 
are generated during the reoxygenation phase of IH, mediate the cellular responses of carotid 
body chemoreceptors to chronic IH (Prabhakar, 2001). This may occur via a ROS-induced 
elevation of Ca2+ levels in glomus cells of carotid bodies, which enhances the release of 
neurotransmitters, ultimately leading to increased hypoxic sensitivity of carotid body 
  
chemoreceptors (Fig. 2; Prabhakar, 2001). Alternatively, ROS might act at the level of oxygen-
sensitive K+ channels to alter the sensitivity of glomus cells to oxygen levels in the blood (Peng 
et al., 2003). Although further experiments are needed to test these possibilities, it has been 
demonstrated that ROS levels are elevated in the carotid bodies of rats chronically treated with 
IH, as evidenced by reduced aconitase enzyme activity, a common marker for ROS (Peng et al., 
2003).  
 
    
Fig. 1. Schematic illustration showing the mechanisms involved in chronic intermittent hypoxia (IH)-induced 
increase in blood pressure. ET-1 = Endothelin-1; ETA = Endothelin receptor A; 5-HT = 5-hydroxytryptamine; sLTF 
= sensory long-term facilitation of the carotid body activity. CA = catecholamines; Ang II= angiotensin II; SNA= 
sympathetic nerve activity; BP= Arterial blood pressure. (Adapted from Prabhakar & Kumar, 2010.)  
 
Furthermore, the increased hypoxic sensitivity of carotid bodies, seen in chronic-IH 
induced animals, has been shown to be associated with an increase in expression of endothelin-1 
(ET-1; Rey et al., 2006). ET-1 is a vasoactive peptide that acts as an excitatory modulator of 
carotid body chemoreception. Therefore, an increase in ET-1 expression can lead to an increase 
in carotid body activity. Indeed, a study by Rey et al. (2006) showed that an increased expression 
  
of ET-1 is partly responsible for carotid body hyperactivity seen in chronic-IH treated cats. This 
finding was supported by that of Pawar et al. (2009), which revealed that the chronic IH-induced 
increase in the hypoxic response of carotid bodies involves a ROS-mediated upregulation of ET-
1 in rats. Collectively, these findings suggest that chronic IH-induced increase in ET-1 
expression is partly responsible for the hypersensitivity of carotid body chemoreceptors in sleep 
apnea patients (Prabhakar & Kumar, 2010). However, whether ET-1 receptor antagonist drugs 
may be beneficial in the treatment of sleep apnea remains to be explored.  
 
 
Fig. 2. Schematic illustration showing the involvement of reactive oxygen species (ROS) in chronic IH-induced short- 
and long-term changes in carotid body sensitivity and gene expression. (Adapted from Prabhakar et al., 2001.) 
 
In addition to its effects on ET-1 expression, chronic IH has also been demonstrated to 
elicit a form of respiratory plasticity known as sensory long-term facilitation (LTF) of the carotid 
body (Peng et al., 2003). Sensory LTF is the progressive and continuous increase in the baseline 
sensory activity of carotid bodies. Because sensory LTF has been shown to be elicited by chronic 
IH-treatment in rats, this may also contribute to the long lasting elevation of sympathetic activity 
seen in sleep apnea patients (Peng et al., 2003). However, the intermediate signaling mechanisms 
involved in evoking sensory LTF are different from those mediating carotid body sensitization to 
the hypoxic response. Of note, one difference is that 5-hydroxytryptamine, not ET-1, mediates 
  
the development of sensory LTF in chronic IH-treated carotid bodies (Fig. 1; Peng et al., 2006). 
Additionally, chronic IH is thought to activate specific genes and transcriptional factors that 
potentiate the long-term adaptation of carotid bodies to chronic IH (Fig. 2; Prabhakar, 2001). 
However, the mechanisms involved in this process remain unclear and understudied, although 
they are thought to likely involve the contribution of ROS (Fig. 2; Prabhakar, 2001). 
 
Sleep apnea promotes blood pressure elevation by attenuating baroreceptor activity 
 Baroreceptors are blood vessel mechanoreceptors that sense and relay blood pressure 
information to the central nervous system to maintain homeostasis. If there is a rise in blood 
pressure, arterial baroreceptors relay this information to the nucleus of the solitary tract (NTS) in 
the brainstem, where a reflex (i.e. baroreflex) is generated to suppress sympathetic nervous 
activity (SNA) and lower blood pressure (Fig. 4).  
In sleep apnea patients, the presence of functional baroreflex activity would likely 
counter the effects of an exaggerated chemoreceptor reflex (i.e. chemoreflex) on the sympathetic 
nervous system. However, the elevated SNA and blood pressure seen in sleep apnea patients is 
also partly attributable to a simultaneous suppression of baroreflex sensitivity, as evidenced by 
attenuated heart rate and vascular resistance responses to activation of baroreceptors in these 
patients (Abboud et al., 2014). In a study by Peng et al. (2012), investigators examined the 
effects of chronic IH on the activity of carotid baroreceptors by measuring the baroreceptor 
activity of rats treated with chronic IH in response to stepwise increases in carotid sinus pressure. 
The study found that the magnitude of increase in baroreceptor activity at higher pressures was 
markedly attenuated in chronic IH-treated rats, as evidenced by a decrease in saturation and 
threshold pressures of carotid baroreceptors, compared with controls (Fig. 3; Peng et al., 2012). 
  
This finding suggests that the attenuation of baroreflex function in sleep apnea patients is at least 
partly due to the effects of chronic IH on baroreceptor activity.  
 
 
Fig. 3. Carotid baroreceptor activity in response to 20 mmHg increases in sinus pressure is attenuated in chronic-IH 
treated rats (B) compared with control rats (A). (Adapted from Peng et al., 2012.) 
 
 
The significance of the chronic IH-induced homeostatic imbalance generated by the 
simultaneous upregulation of chemoreceptor reflex and downregulation of baroreceptor reflex, 
has been subject to some hypotheses. Although not yet proven, it is plausible that this imbalance 
is mediated by elaborate interactions between baroreceptor and chemoreceptor signals in the 
central nervous system. Notably, a study by Silva et al. (2011) revealed an interaction between 
baroreceptor and chemoreceptor signals in neurons of the caudal ventrolateral medulla (CVLM) 
in rats. However, future studies are needed to elucidate whether this interaction is altered by 
sleep apnea-associated chronic IH, and what cardiovascular effects, if any, such an alteration 
might have on patients with sleep apnea.  
Furthermore, the ET-1 peptide, which is involved in mediating hypoxic sensitivity in 
chemoreceptors, is also associated with downregulating baroreceptor sensitivity in chronic IH-
treated rats (Fig. 1; Peng et al., 2012). This suggests that chronic IH may also mediate the 
attenuation of baroreceptor activity via an ET-1-dependent pathway in sleep apnea patients. It is 
  
remarkable that the same peptide, ET-1, is able to exert diametrically opposing effects on 
chemoreceptors and baroreceptors, in that it enhances the activity of the former, and decreases 
activity of the latter. This finding is only further complicated by the fact that ET-1 is a major 
vasoconstrictor hormone that can itself contribute to the elevation of blood pressure seen in 
patients with sleep apnea (Prabhakar & Kumar, 2010).  
 
Sleep apnea alters chemoreflex and baroreflex sensitivity by increasing leptin levels in the 
circulation  
 Chronic IH, in addition to its effects on baroreceptor and chemoreceptor activity, has 
been shown to be associated with an elevation of leptin levels in the circulation (Harsch et al., 
2003). Leptin is a satiety-inducing adipokine that is produced and released into the circulation by 
adipocytes in proportion to adiposity (Ciriello & Moreau, 2012). In healthy humans, leptin acts 
on specific regions of the central nervous system to decrease food intake and increase energy 
expenditure. However, in sleep apnea patients, leptin exerts negative effects on both chemoreflex 
and baroreflex function, which may contribute to the development or progression of 
hypertension and cardiovascular risk in these patients (Ciriello, 2013).  
  Recent studies have identified long form of leptin receptors (Ob-Rb) in the caudal 
regions of the NTS, where baroreceptor afferents predominantly terminate in the brainstem 
(Ciriello, 2013). In addition, it has been demonstrated that injecting leptin into the caudal NTS 
leads to a decrease in the spontaneous discharge rates of NTS neurons that project to 
sympathoinhibitory sites of the CVLM (Ciriello, 2013). Since the CVLM inhibits sympathetic 
outflow by projecting inhibitory neurons to the rostral ventro-lateral medulla (RVLM; Fig. 4), 
suppressing the sympathoinhibitory activity of the CVLM results in a decrease in baroreflex 
sensitivity. Therefore, it is possible that leptin contributes to the attenuation of baroreflex 
  
sensitivity by suppressing the activity of NTS neurons that mediate the projection of 
baroreceptor afferent information to the CVLM. In turn, the CVLM decreases its inhibition of 
sympathoexcitatory RVLM neurons, thereby leading to increased sympathetic activity, and, 
ultimately, elevated blood pressure in sleep apnea patients (Fig. 4). This hypothesis is supported 
by the presence of fenestrated capillaries, enlarged perivascular spaces, and high capillary 
permeability in the caudal NTS, which supports the possibility of leptin being transported 
through the blood-brain barrier to access Ob-Rb-containing NTS neurons in the brainstem (Gross 
et al., 1990; Shaver et al., 1991). However, it is also possible that leptin exerts its effects on other 
Ob-Rb-containing neurons, which send projections to the NTS to alter the brain’s response to 
increased baroreceptor activity evoked by high blood pressure (Barnes et al., 2010).   
 
 
 
Fig. 4. The central baroreceptor pathway showing neural projections from arterial baroreceptors to the brainstem, 
and associated baroreflex responses to maintain homeostasis. Chronic IH leads to a decrease in the spontaneous 
discharge rates of NTS neurons that project to the CVLM, thereby attenuating baroreflex sensitivity and enhancing 
sympathetic activity. NTS = nucleus of the solitary tract, CVLM = caudal ventrolateral medulla; RVLM = rostral 
ventrolateral medulla; IML = intermedial lateral cell column; AMB = nucleus ambiguous. (Adapted from a lecture 
by Dr. John Ciriello.) 
  
Leptin has also been demonstrated to exert effects on the cardiovascular responses 
evoked by the activation of the chemoreflex (Ciriello & Moreau, 2012). Ciriello & Moreau 
(2012) showed that injecting leptin into the NTS of anesthetized rats resulted in a dose-
dependent increase in mean arterial pressure (MAP), heart rate (HR), and renal SNA (Fig. 5). 
Interestingly, the increase in MAP was attributable to an overall increase in SNA, as evidenced 
by the complete abolishment of the MAP response by a peripheral ganglionic blockade; whereas 
the increase in HR was attributable to both an inhibition of parasympathetic nervous activity, and 
an activation of SNA, as a total autonomic blockade was required to completely abolish this 
response (Ciriello & Moreau, 2012). This suggests that, in addition to enhancing sympathetic 
activity, elevated levels of leptin also suppress parasympathetic activity by attenuating vagal 
responses to increased chemoreceptor activity. Collectively, these findings suggest that increased 
leptin levels may contribute to the elevated MAP and SNA seen in sleep apnea patients, by 
altering the sensitivity of the chemoreflex at the level of the NTS (Ciriello & Moreau, 2012). 
However, the exact cellular and subcellular mechanisms by which leptin alters the activity of 
NTS neurons remain unclear. 
 
 
 
Fig. 5. Bar charts summarizing the effects of injecting different concentrations of leptin into the caudal NTS of rats 
on (A) MAP, (B) HR (C) renal SNA. MAP = mean arterial pressure; HR = heart rate; RSNA = renal sympathetic 
nervous activity. (Adapted from Ciriello & Moreau, 2012.) 
  
Sleep apnea augments synthesis/release of vasoconstrictor hormones 
 In addition to its effects on chemoreflex and baroreflex regulation of blood pressure, 
sleep apnea is also linked to an increase in synthesis/release of several vasoactive hormones, 
which act directly on resistance vessels to elevate blood pressure. In sleep apnea patients, these 
hormones are primarily derived from the kidney, adrenal gland, and vascular endothelium 
(Prabhakar & Kumar, 2010).  
 Catecholamines are a family of vasoactive hormones mostly derived from the adrenal 
medulla, that show elevated levels of synthesis/secretion in sleep apnea patients (Marrone et al., 
1993). Two important catecholamines that affect blood pressure regulation in sleep apnea 
patients are epinephrine and norepinephrine, both of which are vasoconstrictor hormones 
released in response to the chronic IH-induced elevation of sympathetic activity (Marrone et al., 
1993; Peng et al., 2006). However, a study by Kuri et al. (2007) revealed another mechanism by 
which chronic IH is able to evoke the secretion of elevated levels of norepinephrine and 
epinephrine in the adrenal medulla of mice. In normal mice, chromaffin cells of the adrenal 
medulla release catecholamines via the Ca2+-mediated fusion of secretory granules to the cell 
surface. However, inducing chronic IH in mice led to an increase in the readily releasable pool of 
secretory granules in adrenal chromaffin cells, independent of sympathetic input (Kuri et al., 
2007). A likely mechanism by which this occurs is via the ROS-mediated activation of protein 
kinase C (PKC), which triggers an increase in recruitment of reserve granules to the readily 
releasable pool in adrenal chromaffin cells. As these granules contain catecholamines, this 
finding suggests that chronic IH facilitates elevated catecholamine secretion from the adrenal 
medulla, via a ROS-mediated signaling pathway (Kuri et al., 2007). Since norepinephrine and 
epinephrine are able to act directly on resistance vessels to increase blood pressure, an increase 
  
in catecholamine secretion likely contributes, at least in part, to the elevated blood pressure seen 
in sleep apnea patients (Prabhakar & Kumar, 2010). 
 Another vasoconstrictor hormone that exhibits increased levels in sleep apnea patients is 
angiotensin II (Ang II), which is involved in the renin-angiotensin system (RAS; Prabhakar & 
Kumar, 2010). An increase in sympathetic activity stimulates the secretion of renin from the 
juxtaglomerular cells of the kidneys, which in turn cleaves angiotensinogen to form angiotensin 
I, which is then converted to Ang II (Fig. 6). In addition to its vasoactive effects, Ang II has been 
demonstrated to increase SNA and blood pressure by activating vasomotor glutamatergic 
sympathetic neurons in the RVLM of rats (Hu et al., 2002). In an epidemiological study by 
Moller et al. (2003), researchers measured 24-hour plasma Ang II levels in patients with OSA, 
and examined whether this was associated with changes in blood pressure. The study revealed a 
strong correlation between sleep apnea severity, Ang II production, and blood pressure (Moller 
et al., 2003). This suggests that sleep apnea promotes the development of hypertension, at least 
in part, by evoking an increased activation of the RAS. However, future studies are needed to 
better elucidate the cellular mechanisms involved in the association between sleep apnea and 
elevated RAS activity.     
 
 
 
Fig. 6. Schematic illustrating the classic renin-angiotensin system cascade. (Adapted from Speth & Geise, 2014.) 
  
Conclusion 
Overall, this review highlights the various mechanisms by which sleep apnea results in 
sustained sympathetic activation and elevated blood pressure. Previous studies on both sleep 
apnea patients and chronic IH-treated animal models have provided crucial insights into the 
mechanisms underlying the development and progression of elevated blood pressure in sleep 
apnea patients. Notably, such studies have shown that sleep apnea is able to alter the activity of 
the sympathetic nervous system and elevate blood pressure by: (1) augmenting the chemoreflex, 
(2) attenuating the baroreflex, (3) increasing leptin levels in the circulation, and (4) promoting 
the synthesis/release of vasoconstrictor hormones. Altogether, the interplay between sympathetic 
activation, leptin production, and vasoactive hormones is able to trigger hypertension, which is a 
risk factor for the development of several cardiovascular diseases including stroke and heart 
failure (Floras, 2013). An increase in blood pressure is also associated with increased heart rate, 
and is a strong predictor of coronary heart disease in humans across all ages (Franklin et al., 
2012). Additionally, sleep apnea is prevalent in patients with stroke, heart failure, and atrial 
arrhythmias, thus highlighting its association with increased cardiovascular risk (Floras, 2013). 
Although understanding the physiological mechanisms involved in sleep apnea-induced 
hypertension has led to the development of newer, more effective interventions for sleep apnea, 
there is as yet no clinical trial evidence that treating sleep apnea significantly alters the rates of 
cardiovascular events (Floras, 2013).  
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